Discover and read the best of Twitter Threads about #GI21
Most recents (2)
#GI21 time for another #Tweetorial🧵 on
#LiquidBiopsies
#CirculatingTumorDNA
#ctDNA
in a very 🎯 “Target-rich” disease
#Cholangiocarcinoma
#HPBCSM
~3️⃣0️⃣% actionable findings
Interestingly we found more #FGFR🧬 fusions on liquid🩸than tissue 🔬. #OncoAlert
@TempusLabs
#LiquidBiopsies
#CirculatingTumorDNA
#ctDNA
in a very 🎯 “Target-rich” disease
#Cholangiocarcinoma
#HPBCSM
~3️⃣0️⃣% actionable findings
Interestingly we found more #FGFR🧬 fusions on liquid🩸than tissue 🔬. #OncoAlert
@TempusLabs
🧵2️⃣ #GI21
#Cholangiocarcinoma is the poster child of actionable aberrations & truly a 🎯“Target-rich” disease.
We focused on %numbers for aberrations for which there’s either an ✅approved drug, guideline endorsement, #clinicaltrials or even off-label reports/cases.👇🏾
#Cholangiocarcinoma is the poster child of actionable aberrations & truly a 🎯“Target-rich” disease.
We focused on %numbers for aberrations for which there’s either an ✅approved drug, guideline endorsement, #clinicaltrials or even off-label reports/cases.👇🏾
🧵3️⃣ #GI21
We often don’t think of #ctDNA based platforms to be as sensitive for detecting fusions; when present it is real & an actionable finding.
Interestingly we found #FGFR🧬fusions
🩸LIQUID>>TISSUE🔬
💭 maybe because of selection bias. #ctDNA filling the void. #OncoAlert
We often don’t think of #ctDNA based platforms to be as sensitive for detecting fusions; when present it is real & an actionable finding.
Interestingly we found #FGFR🧬fusions
🩸LIQUID>>TISSUE🔬
💭 maybe because of selection bias. #ctDNA filling the void. #OncoAlert
@TumorBoardTues #TumorBoardTuesday
Thursday Case 🎀
🧑🎓Great discussion on the Tx of LAPC
✳️Most preferred FFX for this pt
➡️But the only PROSPECTIVE 📋 is w/gem-nab
pubmed.ncbi.nlm.nih.gov/30220407
➡️There are ✅ retrospective 📋 for FFX
thelancet.com/journals/lanon…
➡️For both, resection rate is 10-15%
Thursday Case 🎀
🧑🎓Great discussion on the Tx of LAPC
✳️Most preferred FFX for this pt
➡️But the only PROSPECTIVE 📋 is w/gem-nab
pubmed.ncbi.nlm.nih.gov/30220407
➡️There are ✅ retrospective 📋 for FFX
thelancet.com/journals/lanon…
➡️For both, resection rate is 10-15%
@TumorBoardTues #TumorBoardTuesday
Thursday Case 🎀
Other options for LAPC:
➡️Clinical trials should be our 1st option, if available
✳️TIGER-PAC
✳️KRAS G12D/V siRNA + chemo
✳️Gem-Nab +/- FG-3019
➡️Radiation (despite negative data from LAP-07)
➡️IRE
✳️2 abstracts @ASCO #GI21
Thursday Case 🎀
Other options for LAPC:
➡️Clinical trials should be our 1st option, if available
✳️TIGER-PAC
✳️KRAS G12D/V siRNA + chemo
✳️Gem-Nab +/- FG-3019
➡️Radiation (despite negative data from LAP-07)
➡️IRE
✳️2 abstracts @ASCO #GI21
@TumorBoardTues @ASCO #TumorBoardTuesday
Thursday Case 🎀
We had a poll on what is essentially 2nd line chemo for LAPC
✳️Not surprisingly most recommended gem-nab
➡️There are 2 abstracts @ASCO #GI21 on using nal-iri after progression on FOLFIRINOX
Any thoughts on this?🤔
Thursday Case 🎀
We had a poll on what is essentially 2nd line chemo for LAPC
✳️Not surprisingly most recommended gem-nab
➡️There are 2 abstracts @ASCO #GI21 on using nal-iri after progression on FOLFIRINOX
Any thoughts on this?🤔
